Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Breast Cancer
VEGF receptor 1 and 2 are essential targets to tumor angiogenesis, and we identified that
peptides derived from these receptors significantly induce the effective tumor specific CTL
response in vitro and vivo. According to these findings, in this trial, we evaluate the
safety, immunological and clinical response of those peptides. Patients will be vaccinated
twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide
(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection. Repeated
cycles of the vaccine will be administered until patients develop progressive disease or
unacceptable toxicity, whichever occurs first. In the phase I study, we evaluate the safety
and tolerability of these peptide vaccine. In the following phase II study, we evaluate the
immunological and clinical response of this vaccine therapy.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST)
2 months
Yes
Naohide Yamashita, MD/PhD
Study Chair
The Institute of Medical Science, The University of Tokyo
Japan: Institutional Review Board
Breast-A02-I, II
NCT00677326
May 2008
May 2009
Name | Location |
---|